Nat. Rev. Urol. doi: /nrurol

Slides:

Advertisements

Similar presentations

EORTC : Phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis Ronald B. Keus, Remi A. Nout, Jean-Yves.

Advertisements

Radiotherapy in prostate cancer Dr.Mina Tajvidi Radiation oncologist.

The Health Roundtable 1-1b_HRT1215-Session_HEGI_JOHNSON_WESTMEAD_NSW Volumetric Modulated Arc Therapy for Stereotactic Body Radiotherapy in Early Lung.

Clinical application of TCP ・ NTCP. Lyman JT. Complication probability as assessed from dosevolume histograms. Radiat Res Suppl 1985; 8:S13–S19. Because.

Hypofractionated Radiation Therapy for Early Stage Breast Cancer Patrick J. Gagnon, M.D. Resident, PGY-4 Radiation Medicine, OHSU Providence Hospital Breast.

Prostate Support Group Dr Duncan McLaren Consultant Oncologist.

Hypofractionated radiotherapy for breast cancer

Updates in Prostate Cancer Prepared for GP master class – Sept 2016

Nat. Rev. Urol. doi: /nrurol

Evaluation of biologically equivalent dose escalation, clinical outcome, and toxicity in prostate cancer radiotherapy: A meta-analysis of 12,000 patients.

Nat. Rev. Urol. doi: /nrurol

Figure 4 Types of urinary diversion

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 2 Recruitment of experts to the Delphi study

Figure 3 Birt–Hogg–Dubé (BHD) renal tumour histology

Radiation Oncology New Techniques + Technologies

Nat. Rev. Urol. doi: /nrurol

Figure 3 Semantic model of the active surveillance (AS) timeline

Nat. Rev. Urol. doi: /nrurol

Figure 2 Peptide vaccination using TAA-derived long peptides

Volume 68, Issue 4, Pages (October 2015)

Nat. Rev. Urol. doi: /nrurol

Figure 1 Key elements of the proposed modified Delphi study

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 2 Schema for the phase II Randomized Observation versus

David J. Brenner, Eric J. Hall, Rochelle E. Curtis, Elaine Ron

Figure 3 Treatment algorithm for adult infertile men with varicoceles

Figure 3 Algorithm for the determination of the clinical

Figure 4 Dosimetric comparison of LDR‑BT versus HDR‑BT

Nat. Rev. Urol. doi: /nrurol

Figure 2 Nonmalignant tissue can be spared from radiation

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Figure 6 Image sequence demonstrating coronal cuts on MRI

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 2 Host immune responses, not the radiosensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Radiation Therapy for Prostate Cancer

Figure 3 Template for standard pelvic lymphadenectomy

Figure 1 Comparison of LDR‑BT, HDR‑BT, and EBRT

Nat. Rev. Urol. doi: /nrurol

the SNP profile using 26 prostate cancer GWAS risk SNPs

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 2 Logistical requirements for autologous

Nat. Rev. Urol. doi: /nrurol

Figure 2 The evolution of brachytherapy for prostate cancer

Volume 14, Issue 11, Pages (October 2013)

Nat. Rev. Urol. doi: /nrurol

Volume 9, Issue 4, Pages (April 2008)

Nat. Rev. Urol. doi: /nrurol

Figure 4 The grey zone between active

Implementation of hypofractionated prostate radiation therapy in the United States: A National Cancer Database analysis William A. Stokes, MD, Brian.

Hemithoracic Radiotherapy After Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma: A Dosimetric Comparison of Two Well-Described Techniques

Nat. Rev. Urol. doi: /nrurol

Volume 371, Issue 9618, Pages (March 2008)

Figure 3 Craniospinal irradiation proton therapy for medulloblastoma

Nat. Rev. Urol. doi: /nrurol

Figure 3 Target volume definitions

Figure 3 Determination of the primary site

Nat. Rev. Urol. doi: /nrurol

Stereotactic Body Radiotherapy for Central Lung Tumors

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international,

Presentation transcript:

Nat. Rev. Urol. doi:10.1038/nrurol.2016.106 Figure 1 Radiotherapy fractionation schedules for the management of patients with prostate cancer Figure 1 | Radiotherapy fractionation schedules for the management of patients with prostate cancer. Fractionation of a prescribed radiation dose over several treatment sessions is used to protect nonmalignant tissues adjacent to the tumour. Technological developments have improved the precision of radiation delivery, enabling increased fraction doses and shorter treatment schedules without compromising efficacy but increasing patient compliance. Conventionally fractionated radiotherapy is usually delivered in 38–40 sessions of single 1.8–2 Gy fractions, resulting in an 8–9-week treatment duration. In moderate hypofractionation, 19–30 sessions of single 2.4–4 Gy fractions are given over a total of 4–6 weeks. Extremely hypofractionated radiotherapy consists of 4–5 treatment sessions of 6–10 Gy doses each and treatment is usually concluded after 1–2 weeks. Arcangeli, S. & Greco, C. (2016) Hypofractionated radiotherapy for organ-confined prostate cancer: is less more? Nat. Rev. Urol. doi:10.1038/nrurol.2016.106